Abstract
We tested the ability of a novel DNA methylation biomarker set to distinguish metastatic pancreatic cancer cases from benign pancreatic cyst patients and to monitor tumor dynamics using quantitative DNA methylation analysis of cell-free DNA (cfDNA) from blood samples. The biomarkers were able to distinguish malignant cases from benign disease with high sensitivity and specificity (AUC = 0.999). Furthermore, the biomarkers detected a consistent decline in tumor-derived cfDNA in samples from patients undergoing chemotherapy. The study indicates that our liquid biopsy assay could be useful for management of pancreatic cancer patients.
Original language | English (US) |
---|---|
Article number | 28 |
Journal | Clinical Epigenetics |
Volume | 14 |
Issue number | 1 |
DOIs | |
State | Published - Dec 2022 |
ASJC Scopus subject areas
- Molecular Biology
- Genetics
- Developmental Biology
- Genetics(clinical)